Skip to main content

Table 2 Virologic and Immunologic Outcomes for patients initiating HAART using an Intention to Treat Analysis.

From: Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study

Outcome 1 year 5 years 8 years
HAART Era Total Early Late Total Early Late Total Early Late
Median (IQR) # of viral loads available per patient 4 (3-6) 4 (3-6) 5 (3-6) 17 (12-23) 18 (12-24) 15 (12-19) 26 (18-35) 26 (18-35) 20 (15-27)
Virologic Suppression (n) 1759 1216 543 1063 868 195 735 707 28
   Suppresseda 1135 (64.5) 693 (57.0)g 442 (81.4) 674 (63.4) 508 (58.5)g 166 (85.1) 487 (66.3) 464 (65.6) 23 (82.1)
   Always Suppressedb 864 (49.1) 478 (39.3)g 386 (71.1) 244 (23.0) 172 (19.8)g 72 (36.9) 112 (15.2) 104 (14.7) 8 (28.6)
   Ever Suppressedc 1391 (79.1) 890 (73.2) 501 (92.3) 991 (93.2) 800 (92.2) 191 (97.9) 707 (96.2) 680 (96.2) 27 (96.4)
Virologic Failured 629 (35.8) 525 (43.2)g 104 (19.2) 594 (55.9) 527 (60.7)g 67 (34.4) 496 (67.5) 482 (68.2)g 14 (50. 0)
   Never Suppressede 368 (20.9) 326 (26.8)g 42 (7.7) 72 (6.8) 68 (7.8)g 4 (2.1) 28 (3.8) 27 (3.8) 1 (3.6)
   Reboundf 261 (14.8) 199 (16.4)g 62 (11.4) 522 (49.1) 459 (52.9)g 63 (32.3) 468 (63.7) 455 (64.4) 13 (46.4)
Mean CD4, cells/mL 488 ± 267 469 ± 268 530 ± 262 571 ± 306 562 ± 305 611 ± 307 556 ± 306 552 ± 301 657 ± 398
CD4 Change 143 ± 180 126 ± 171g 179 ± 193 220 ± 271 214 ± 270 247 ± 278 209 ± 288 206 ± 284 263 ± 362
CD4 Increase ≥ 30% 880 (60.0) 564 (56.9) 316 (66.5) 583 (66.9) 461 (65.3) 122 (73.5) 381 (62.5) 365 (62.6) 16 (59.3)
CD4 Increase ≥ 50% 665 (45.4) 418 (42.2) 247 (52.0) 489 (56.1) 385 (54.5) 104 (62.7) 331 (54.3) 318 (54.5) 13 (48.1)
  1. Patients with missing lab values were excluded on that date
  2. aNumber (%) of patients at the given time point who have one undetectable viral load
  3. bNumber (%) of patients suppressed at 6-months and then at all visits through indicated time point
  4. cNumber (%) of patients having an undetectable viral load at least once through indicated time point
  5. dNumber (%) of patients at the given time point who have either had at least one episode of rebound or never suppressed
  6. eNumber (%) of patients never having an undetectable viral load
  7. fNumber (%) of patients ever having a rebound event (undetectable, then detectable + detectable)
  8. gSignificant difference comparing early versus late era (p < 0.05)